United Airline’s Quarter: Less Crash More Burn
United Airlines reported a second-quarter net loss of $5.79 per share and $1.48 billion in revenue, compared with consensus estimates that called for a net loss of $9.02 in EPS and $1.32 billion in…
All Work
Chris Lange
Snap Gets the Picture in Q2 But Investors Not Happy
Social media company Snap reported a second-quarter net loss of $0.09 per share and $454 million in revenue, compared with consensus estimates that called for a per-share loss of $0.09 and $438.09 million in…
Was Amazon Under Too Much Stress for Prime Day During the Pandemic?
Amazon.com is pushing back its much-lauded Prime Day due to the pandemic. Will this cause near-term pain for investors?
BioNTech Raises Over $400 Million to Boost COVID-19 Efforts
BioNTech is one of the leading companies in the race to a COVID-19 vaccine. With its shares up more than 160% year to date, it’s time to capitalize.
Late-Stage Diabetes Study Sets the Stage for Lexicon Pharma
Lexicon Pharmaceuticals shares surged on Tuesday after the company announced positive topline data for its late-stage studies in type 2 diabetes.
Moleculin Biotech’s Antimetabolites COVID-19 on Track for Treatment Status
Moleculin Biotech joins the ever-expanding list of coronavirus stocks as the company announced that a second round of independent laboratory testing has confirmed the antiviral activity of WP1122.
Why Immuron’s New COVID-19 Study Is a Game Changer
Immuron continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome due to the virus that causes COVID-19.
Declining Revenues Aren’t Enough to Hold IBM Back in Q2
IBM reported Monday after the markets closed that posted $2.18 in earnings per share (EPS) and $18.1 billion in revenue in the second quarter versus analysts' calls for $2.07 in EPS and $17.72 billion…
Why This FDA Clearance Is a Big Deal For Sorrento Therapeutics
Sorrento Therapeutics has announced that its treatment for COVID-19 had cleared its Phase 2 study in hospitalized patients with moderate to severe coronavirus infections.
Nikola Warrant Holders Must Be Happy With This
Nikola is in for an interesting trading week now that its warrants from its initial public offering have become exercisable.
Analysts Keep Stepping Over Each Other With Higher Amazon Price Targets
Analysts have been tripping all over themselves chasing Amazon higher for quite a while. A couple more analysts have come out with new higher price targets for the e-commerce empire.
GlaxoSmithKline Joins the Race for a COVID-19 Vaccine
GlaxoSmithKline has announced that it is acquiring a 10% stake in the German biopharma firm CureVac.
Pfizer and BioNTech Make Another Big Step for COVID-19 Vaccine
BioNTech and Pfizer are leading the pack of COVID-19 vaccine stocks as this collaboration came out with more positive news regarding their ongoing German Phase 1/2 study.
AT&T, Snap, Tesla, Twitter and More Major Earnings Coming This Week
24/7 Wall St. offers a preview of what to expect from some of the most anticipated quarterly results due this week, including AT&T, Philip Morris and United Airlines.
IBM, Intel, Microsoft, Verizon and More Dow Earnings Coming This Week
24/7 Wall St. has put together a preview of those Dow companies scheduled to report their quarterly results this week including Coca-Cola, Intel, Microsoft and Verizon.
PhaseBio’s COVID-19 Treatment Is on the Way
PhaseBio Pharmaceuticals announced early on Friday that it has initiated its midstage study evaluating a treatment for the novel coronavirus.
8 Coronavirus Stocks That Can Deliver Even More Upside Ahead
The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could still see…
Too Many Plot Twists In Netflix Earnings to Keep Investors Interested
After markets closed Thursday, streaming video giant Netflix reported $1.59 in earnings per share (EPS) and $6.15 billion in revenue, compared with consensus estimates that called for $1.81 in EPS and $6.08 billion.
The Driving Force Behind Morgan Stanley’s Record Quarter
Morgan Stanley released better than expected second-quarter earnings report before the opening bell on Thursday, due in part to strong Sales and Trading revenues.
Johnson & Johnson’s Impressive Quarter, Still Held Back by One Segment
Johnson & Johnson released better than expected quarterly results and guidance before the markets opened on Thursday.